Short answer
Esperion Therapeutics, Inc. (ESPR) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets). CVR holders eligible for up to $100 million in aggregate contingent cash payments, tied to specified milestones.
- This filing includes Item 3.01, an item that often signal trouble.
Esperion Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- CVR holders eligible for up to $100 million in aggregate contingent cash payments, tied to specified milestones
- CVRs non-transferable except in limited circumstances, reducing liquidity for holders
- Merger triggered a Make-Whole Fundamental Change for 5.75% convertible notes due 2030
- Note conversions receive $1,232.62 cash plus 390.0701 CVRs per $1,000 principal amount
- New loan agreement adds BioPharma Credit lenders and collateral arrangements supporting the merger financing structure
Item 1.02 · Termination of a Material Definitive Agreement
- Esperion repaid all outstanding debt under the December 2024 credit agreement on July 13, 2026
- Termination coincided with new Loan Agreement entry and Merger completion
- Debt refinancing replaces the prior lender arrangement, potentially resetting financing terms and liquidity obligations
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Esperion became a wholly owned subsidiary of Parent, ending its public-company status
- Shareholders received $3.16 cash per share plus one CVR tied to milestone payments
- CVRs offer up to $100 million aggregate additional cash, subject to specified milestones and tax withholding
- Parent paid approximately $1.1 billion in cash, funded through equity contributions and debt financing
- RSUs and in-the-money options vested and converted into cash plus CVRs, while certain out-of-the-money options received no consideration
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 links the financial obligation to the transaction described in the filing’s Introductory Note and Item 1.01
- Investor focus: referenced agreement may create material payment obligations or liquidity impacts for Esperion
- Key terms, including amount, maturity and interest, require review of Item 1.01 and the referenced exhibit
Item 3.01 · Notice of Delisting
- Esperion common stock will be delisted from Nasdaq following consummation of the merger
- Company requested Nasdaq file Form 25 with the SEC to remove and deregister shares under Exchange Act Section 12(b)
- Planned Form 15 filing would suspend Esperion’s Exchange Act reporting obligations under Sections 13 and 15(d)
- Investors should expect loss of Nasdaq trading and reduced public-company disclosure after merger completion
Item 3.03 · Material Modification to Rights of Security Holders
- Rights impact derives from related Items 2.01, 3.01, 5.01 and 5.03
- Investors should review those sections for transaction, listing, control and charter implications
Item 5.01 · Changes in Control of Registrant
- Esperion became wholly owned by Parent upon merger completion
- Change of control removes Esperion as an independent public company
- Merger terms, transaction impact and leadership changes addressed in Items 2.01 and 5.02
Item 5.02 · Departure/Election of Directors or Officers
- Merger completion removed six incumbent directors, including CEO-related and legacy board members
- Justin Bateman and Ankit Pareek became directors, aligning board composition with the merger partner
- Board turnover signals post-merger governance transition and potential changes in strategy, oversight and capital allocation
- Investors should assess new directors’ independence, expertise and influence over the combined company
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Merger closing triggered complete restatement of Esperion’s certificate of incorporation and bylaws
- New governance documents became effective at the merger’s Effective Time
- Amendments likely align corporate governance with the completed merger and resulting ownership structure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Esperion Therapeutics, Inc. 8-K filings
Get the next ESPR 8-K as it lands
Follow ESPR for push alerts, or ask the research agent what this filing means.